Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. by Raval, RR et al.
MOLECULAR AND CELLULAR BIOLOGY, July 2005, p. 5675–5686 Vol. 25, No. 13
0270-7306/05/$08.000 doi:10.1128/MCB.25.13.5675–5686.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and
HIF-2 in von Hippel-Lindau-Associated
Renal Cell Carcinoma
Raju R. Raval,1† Kah Weng Lau,1 Maxine G. B. Tran,2 Heidi M. Sowter,3 Stefano J. Mandriota,1
Ji-Liang Li,3 Christopher W. Pugh,1 Patrick H. Maxwell,2 Adrian L. Harris,3
and Peter J. Ratcliffe1*
The Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford OX3 7BN,1 Cancer Research UK
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital,
Oxford OX3 9DU,3 and Renal Section, Imperial College of Science, Technology and Medicine,
Hammersmith Hospital, Du Cane Road, London W12 0NN,2 United Kingdom
Received 29 November 2004/Returned for modification 10 December 2004/Accepted 27 March 2005
Defective function of the von Hippel-Lindau (VHL) tumor suppressor ablates proteolytic regulation of
hypoxia-inducible factor  subunits (HIF-1 and HIF-2), leading to constitutive activation of hypoxia
pathways in renal cell carcinoma (RCC). Here we report a comparative analysis of the functions of HIF-1 and
HIF-2 in RCC and non-RCC cells. We demonstrate common patterns of HIF- isoform transcriptional
selectivity in VHL-defective RCC that show consistent and striking differences from patterns in other cell types.
We also show that HIF- isoforms display unexpected suppressive interactions in RCC cells, with enhanced
expression of HIF-2 suppressing HIF-1 and vice-versa. In VHL-defective RCC cells, we demonstrate that the
protumorigenic genes encoding cyclin D1, transforming growth factor alpha, and vascular endothelial growth
factor respond specifically to HIF-2 and that the proapoptotic gene encoding BNip3 responds positively to
HIF-1 and negatively to HIF-2, indicating that HIF-1 and HIF-2 have contrasting properties in the
biology of RCC. In keeping with this, HIF- isoform-specific transcriptional selectivity was matched by
differential effects on the growth of RCC as tumor xenografts, with HIF-1 retarding and HIF-2 enhancing
tumor growth. These findings indicate that therapeutic approaches to targeting of the HIF system, at least in
this setting, will need to take account of HIF isoform-specific functions.
Associations between microenvironmental hypoxia, activa-
tion of hypoxia pathways, and aggressively malignant pheno-
types are observed across a range of cancers, focusing attention
on molecular dissection of these pathways and how they con-
tribute to tumor biology (8, 9). Important insights have been
gained through the definition of hypoxia-inducible factor
(HIF) as a key transcription factor regulating oxygen-depen-
dent gene expression. HIF is an / heterodimeric DNA bind-
ing complex that directs an extensive transcriptional response
involving the induction of genes with important roles in several
aspects of tumor biology such as angiogenesis, glucose/energy
metabolism, cellular growth, metastasis, and apoptosis (37).
The HIF system is regulated through the activity and abun-
dance of HIF- subunits. To date, three HIF- isoforms have
been described, with the best characterized being HIF-1 and
HIF-2. In cancer, the HIF system is upregulated both by
microenvironmental hypoxia and by genetic events that lead to
enhanced translation or stability of HIF- (37). Activation of
HIF in cancer has been shown to contribute to the classical
tumor phenotypes of upregulated glycolysis and angiogenesis
(23, 28, 34, 36), leading to widespread interest in the HIF
system as a target in cancer therapeutics (37). However,
though most studies have indicated that HIF activation con-
tributes positively to tumor growth (37), studies of experimen-
tal tumors derived from cells with genetic defects in the HIF
system have not universally supported this (5). Moreover, HIF
target genes encode a wide range of products, some of which,
such as the Bcl-2-related proapoptotic protein BNip3, might be
predicted to have antitumorigenic properties (3, 15).
The most direct link between genetic events that predispose
to cancer and activation of the HIF pathway is observed in
tumors associated with inactivation of the von Hippel-Lindau
(VHL) tumor suppressor gene, particularly VHL-associated
clear-cell renal cell carcinoma (RCC) (29). In hereditary RCC,
associated with VHL disease, affected individuals bear a germ
line mutation in VHL, with somatic inactivation of the second
allele occurring as an early event in RCC development. In
sporadic RCC, both VHL alleles are commonly subject to
somatic mutation. Though several functions have been pro-
posed for VHL, the best understood is in the regulation of
HIF, where VHL acts as the recognition component of an E3
ubiquitin ligase complex that targets HIF- subunits to the
ubiquitin/proteasome degradation pathway following oxygen-
dependent prolyl hydroxylation (16). In VHL-defective cells,
HIF- accumulates irrespective of hydroxylation, the HIF sys-
tem is activated, and a constitutively hypoxic pattern of gene
expression is observed. Interestingly, VHL-defective RCC cells
show an unusual bias toward HIF-2 rather than HIF-1 ex-
pression (22, 29). Though transfection studies have indicated
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that HIF-1 and HIF-2 activate hypoxia response element-
linked reporter genes in a similar manner (42, 45), studies of
genetic inactivation have indicated differences, with most stud-
ies emphasizing the importance of HIF-1 in directing the
transcriptional response to hypoxia (11, 13, 32, 35, 39).
Physiologically, the VHL E3 ubiquitin ligase plays a similar
role in the regulation of both HIF-1 and HIF-2. Both pro-
teins contain two conserved sites of prolyl hydroxylation that
are independently targeted by a single hydroxyproline binding
site within the  domain of VHL (10, 30). This process is
disrupted by all RCC-associated VHL mutations tested to date
(17), and overexpression of a HIF-2 gene that escapes VHL-
mediated destruction due to mutation of one or both prolyl
hydroxylation sites blocks the tumor suppressor action of VHL
in experimental tumors grown from transplanted RCC cells
(18, 19). In addition, small interfering RNA (siRNA)-medi-
ated downregulation of HIF-2 itself suppresses tumor forma-
tion by VHL-defective RCC cells (18, 49). These findings have
strongly suggested that upregulation of the HIF system plays a
functional role in VHL-associated RCC. However, in apparent
contrast, other investigators have found that overexpression of
a HIF-1 gene that is mutated at one of the prolyl hydroxyla-
tion sites did not block the tumor suppressor action of VHL in
RCC cells (27), raising the possibility that despite their simi-
larities, and common upregulation in many types of cancer,
HIF-1 and HIF-2 may have nonequivalent effects in the
pathogenesis of VHL-associated RCC.
To better understand the role of the HIF pathway in VHL-
associated RCC, we have examined the transcriptional selec-
tivity for the HIF-1 and HIF-2 isoforms among a group of
genes that are expressed in VHL-defective RCC and have
compared responses in VHL-defective RCC with those in
other cell lines. We show that HIF target genes show remark-
able selectivity for HIF-1 and HIF-2, that patterns observed
in VHL-defective RCC differ significantly from those in other
cells, and that the transcriptional selectivity observed in RCC
for HIF-2 versus HIF-1 correlates at least in part with pre-
dicted positive or negative effects on tumor growth. In keeping
with this, we show that effects on RCC tumor formation are
nonequivalent, with HIF-2 overexpression promoting and
HIF-1 expression retarding tumor growth. In addition, we
demonstrate that HIF- isoforms display reciprocal suppres-
sive interactions in VHL-defective cells that may contribute to
the unusual expression pattern of low HIF-1 and high HIF-2
in RCC.
MATERIALS AND METHODS
Cell culture. All cell lines were maintained in Dulbecco modified Eagle me-
dium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 IU/ml
penicillin, and 50 g/ml streptomycin, except for the human kidney 2 (HK-2) cell
line, which was maintained in Keratinocyte-SFM supplemented with 5 ng/ml
recombinant epithelial growth factor and 0.05 mg/ml bovine pituitary extract
(GIBCO-BRL 17005-042). The 786-O cells stably transfected with either an
empty vector (PRC3) or VHL (WT-8), the A498 cells stably transfected with
VHL (all gifts from William G. Kaelin, Jr.), and the RCC4 cells stably trans-
fected with VHL (RCC4/VHL) (29) were maintained in G418 (1 mg/ml). Cells
were grown in normoxia (21% O2) or hypoxia (1% O2) in a Napco 7001 incu-
bator (Precision Scientific). Desferrioxamine and cycloheximide were obtained
from Sigma, and dimethyloxalylglycine (MMOG) was a gift from Christopher J.
Schofield. For determination of proliferation in standard monolayer culture,
approximately 15,000 cells per well were seeded in six-well plates. Each day, cells
from three wells of each cell line were harvested and passed through a Coulter
counter, with gating between 14 m and 42 m.
RNA analysis. Total RNA was extracted in RNAzol B (Biogenesis) and dis-
solved in hybridization buffer [80% formamide, 40 mM piperazine-N,N-bis(2-
ethanesulfonic acid) (PIPES), 400 mM sodium chloride, 1 mM EDTA (pH 8)].
Forty-five micrograms of total RNA was assayed by RNase protection as previ-
ously described, with U6 small nuclear RNA serving as an internal control (45).
The cyclin D1 (CCND1) riboprobe protected a fragment between bases 3902 and
4060 of the 3 untranslated region (accession no. NM_053056).
siRNA preparation and transfection. RNA duplexes targeting HIF-1 and
HIF-2 were used as previously described (39). Silencer Negative Control siRNA
(Ambion) and Oligofectamine Reagent alone (Invitrogen) were used in control
experiments. Cells were plated at 30% confluence in six-well plates in antibiotic-
free medium 24 h before transfection. siRNA duplexes (20 nM) were transfected
twice at 24-h intervals using Oligofectamine Reagent.
Retroviruses. HIF-1, HIF-2, and control retroviruses were produced using
the bicistronic expression plasmids pLZRS-IRES-GFP (14) and pBMN-Z-IRES-
Neo (gifts from Maarten van Lohuizen and Garry Nolan, respectively), and
Phoenix Amphotropic packaging cells (gift from Garry Nolan). HIF-1 and
HIF-2 coding sequences were inserted into the expression plasmids (with re-
moval of the LacZ coding sequence from pBMN-Z-IRES-Neo) using standard
recombinant methods that will be provided on request. The HIF-2 DNA bind-
ing domain mutant (amino acid residues 24 to 29, RCRRSK to ACAASA) (19)
was created in pCDNA3-HIF-2 and subcloned into pLZRS-IRES-GFP follow-
ing verification of the mutant sequence. Stable polyclonal pools of 786-O cells,
infected with retrovirus produced from the pBMN-Z-IRES-Neo plasmids with
HIF-1, HIF-2, or no insert were selected in G418 (1 mg/ml).
For retrovirus production, Phoenix cells were plated at 50% confluence in a
6-cm dish, incubated for 24 h, transfected with 10 g of the appropriate retroviral
vector using Fugene 6 (Roche), and then incubated at 37°C. After 24 h, cells were
replated in a 75-cm2 flask and grown for another 24 h at 32°C. Viral supernatant
was collected and filtered (0.45-m pore size; Millipore) and then supplemented
with 4 g/ml Polybrene (Sigma). Target cells for infection were plated at 30%
confluence in six-well plates for 24 h, and medium was then replaced with 0.5 ml
of the appropriate viral supernatant with Polybrene for 6 h, followed by super-
natant diluted 1:3 with standard growth medium for another 42 h at 37°C. The
infection protocol was repeated with fresh retrovirus over a further 48 h. Cells
were then harvested or selected in G418 as appropriate. Infection efficiencies
between 75% and 95% were routinely achieved in unselected cells using pLZRS-
IRES-GFP, as detected by FACS analysis for green fluorescent protein (GFP).
Immunoblotting. Cells were rinsed in ice-cold phosphate-buffered saline
(PBS) and then lysed in urea-sodium dodecyl sulfate (SDS) buffer (6.7 M urea,
10 mM Tris-Cl [pH 6.8], 1 mM dithiothreitol, 10% glycerol, 1% SDS) supple-
mented with Complete protease inhibitor cocktail (Roche). Protein concentra-
tions were determined using the DC protein assay kit (Bio-Rad), and extracts
were normalized for protein content. Whole-cell extracts were resolved by SDS-
polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluo-
ride membrane (Millipore). Primary antibodies were mouse monoclonal anti-
bodies against HIF-1 (54; Transduction Labs), HIF-2 (190b) (45), cyclin D1
(ab3; Oncogene Research Products), carbonic anhydrase IX (M75) (48), BNip3
(ANa40; Sigma), and -tubulin (2-28-33; Sigma) and rabbit polyclonal antibody
against glucose transporter-1 (ab652; abcam). Detection was with the ECL Plus
system (Amersham Biosciences) and horseradish peroxidase-conjugated second-
ary anti-mouse or anti-rabbit antibodies (DAKO). Membranes were later stained
with Coomassie blue to verify equal loading.
Vascular endothelial growth factor (VEGF) and transforming growth factor
alpha (TGF-) enzyme-linked immunosorbent assays. Secreted levels of VEGF
were measured using a Quantikine human VEGF immunoassay kit (R&D Sys-
tems) and normalized to cell number. For measurement of TGF- in cell lysates,
cells were harvested in NP-40 lysis buffer, lightly vortexed on ice for 30 min, and
then used in the Quantikine human TGF- immunoassay kit (R&D Systems).
TGF- levels were normalized to total cellular protein content.
Clinical material and immunohistochemistry. Kidney specimens obtained at
nephrectomy from seven VHL patients were formalin fixed and embedded in
paraffin wax. Sections (3 m) were mounted, dewaxed, rehydrated, and stained
with primary antibodies (using antigen retrieval for HIF-1, HIF-2, and cyclin
D1); then, following antigen-antibody complex detection, sections were counter-
stained with hematoxylin, dehydrated, and visualized as previously described
(26). Cyclin D1 detection was with rabbit anti-human cyclin D1 (SP4; Neomar-
kers) at 1/200, and BNip3 detection was with mouse monoclonal anti-human
BNip3 (ANa40; Sigma) at 1/100.
Xenograft assays in nude mice. Unselected 786-O cells infected with the
pLZRS-IRES-GFP-based HIF-1, HIF-2, or control virus (experiment 1) or
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G418 selected polyclonal pools of 786-O cells infected with the pBMN-Z-IRES-
Neo based HIF-1, HIF-2, or control virus (experiments 2 and 3) were released
by trypsinization and resuspended in PBS, and 107 cells in 100 l PBS were
injected, with or without 100 l of Matrigel (BD Biosciences), subcutaneously
into the dorsal flanks of nu/nu mice. Tumor size was measured twice weekly using
calipers, and the xenografts were excised when they reached the maximum
permitted size (1.44-cm2 surface area) in the first two experiments, where three
sets of five mice each were injected in parallel. In the third set of xenografts, cells
were injected into both flanks of three sets of seven mice each and the tumors
from all of the groups were excised and weighed at a single time point specified
by the first tumor reaching the maximum permitted size.
RESULTS
HIF- isoform-specific regulation of cyclin D1 in RCC cells.
We first focused our analysis on the regulation of cyclin D1, a
protein with a well-established role in oncogenesis that has
recently been identified as a VHL-regulated gene product (2,
47). This work has demonstrated that cyclin D1 is strongly
upregulated in RCC cell lines and tumor specimens and is
down regulated by reintroduction of wild-type VHL into VHL-
defective RCC cells. Interestingly, several groups, including
our own, have shown that cyclin D1 displays hypoxia-inducible
behavior in RCC cells re-expressing wild-type VHL but not in
other cell types (1, 2, 46). This is illustrated in Fig. 1A for cyclin
D1 mRNA in 786-O (PRC3) cells and in the stable transfectant
786-O/VHL (WT-8) expressing wild-type VHL.
The unusual cell specificity of this response raised questions
as to the nature of the hypoxia pathways involved. To address
this, 786-O/VHL (WT-8) cells were exposed to the iron che-
lator desferrioxamine and the 2-oxoglutarate analog MMOG,
both of which are powerful inhibitors of HIF hydroxylases. As
shown in Fig. 1B, both compounds strongly induced cyclin D1
mRNA. 786-O cells were next transfected with siRNAs that
target HIF-1 and HIF-2 specifically. Cyclin D1 mRNA lev-
els were clearly suppressed by siRNA directed against HIF-2,
but not HIF-1 (Fig. 1C). Despite the cell type specificity,
these results indicate that hypoxia-inducible expression of cy-
clin D1 is mediated by the HIF system. They are consistent
with the unusual pattern of HIF- isoform expression in 786-O
cells that express HIF-2 alone and correlate with data pub-
lished during the course of this work demonstrating that
HIF-2 overexpression can enhance cyclin D1 expression in
RCC cells (1). To analyze this further, 786-O cells were in-
fected with retrovirus, produced using the pLZRS-IRES-GFP
vector, expressing (in addition to GFP) either HIF-1, HIF-2,
or no additional sequence. As anticipated, infection with ret-
rovirus expressing HIF-2 further induced cyclin D1 at both
the mRNA (Fig. 1D) and protein (Fig. 1E) levels. However, in
contrast, infection of 786-O cells with virus expressing HIF-1
downregulated cyclin D1 (Fig. 1D and E, upper part), a result
that was paralleled by downregulation of HIF-2 (Fig. 1E,
lower part). Further experiments were performed with RCC4,
a VHL-defective cell line that expresses HIF-1 in addition to
HIF-2. Transfection of RCC4 cells with siRNAs targeting
HIF-1 or HIF-2 demonstrated clear specificity of cyclin D1
for HIF-2 with no discernible downregulation or even slight
upregulation by HIF-1 siRNA (Fig. 2A). Infection of RCC4
cells with retroviruses expressing HIF- isoforms demon-
strated induction by HIF-2, but not HIF-1 (Fig. 2B).
Reciprocal interaction between HIF-1 and HIF-2 levels
in RCC. Overall, these findings indicate that cyclin D1 is a
FIG. 1. Regulation of cyclin D1 (CCND1) in 786-O cells. (A and B)
RNase protection assay of CCND1 mRNA and U6 snRNA (loading
control) in 786-O (PRC3) and 786-O/VHL (WT-8) after exposure to
normoxia (N), hypoxia (H), 100 M desferrioxamine (D), or 1 mM
MMOG (M) for 18 h. (C) RNase protection assay of HIF-2 mRNA
and CCND1 mRNA in 786-O/VHL (WT-8) after treatment for 48 h
with Oligofectamine alone (), HIF-1-directed siRNA (H1), HIF-
2-directed siRNA (H2), or control siRNA (C). (D) RNase protection
assay of CCND1 mRNA and U6 snRNA in 786-O cells infected with
retroviral supernatants made from pLZRS containing GFP alone (G),
HIF-1 (H1), or HIF-2 (H2). (E) Immunoblots, with the indicated
antibodies, of whole-cell lysates from 786-O cells that were infected
with retroviral supernatants made from pLZRS containing GFP alone
(G), HIF-1 (H1), or HIF-2 (H2). Two independent experiments for
each condition are shown in panel E.
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specific HIF-2 target in RCC cells. Unexpected down regu-
lation of both cyclin D1 and HIF-2 when 786-O cells were
infected with retrovirus expressing HIF-1 also suggested that
HIF- isoforms display an unanticipated interaction in this cell
type. Further analysis of this in RCC4 cells indicated that
overexpression of HIF-2 strikingly downregulated HIF-1,
suggesting that this interaction is reciprocal (Fig. 2B, middle
part). To test whether interactions occur between the endog-
enous HIF- proteins, we re-examined the effects of siRNA.
Basal levels of HIF-2 were not affected by HIF-1 siRNA
under these conditions; however, upregulation of HIF-1 pro-
tein was observed following suppression of HIF-2 (Fig. 2C).
To determine how general these interactions are in RCC cells,
further experiments were performed with SKRC28 cells (7),
another VHL-defective RCC cell line expressing both HIF-1
and HIF-2. Similar results were obtained, with clear suppres-
sion of HIF-1 following overexpression of HIF-2 (Fig. 2D)
and induction of HIF-1 following siRNA-based suppression
of HIF-2 (Fig. 2E). Though the reciprocal effects of HIF-1
on HIF-2 that were observed in 786-O cells were not seen in
these experiments, such effects did occur under other condi-
tions. For instance, RCC4 cells retain low-level regulation of
HIF-2 by HIF hydroxylase inhibition. When examined fol-
lowing exposure to the hydroxylase inhibitor MMOG, modest
but reproducible increases in HIF-2 were observed following
siRNA-mediated suppression of HIF-1 levels (Fig. 2F). Den-
sitometric analysis showed that in comparison to a constitutive
species, -tubulin, the increase in HIF-2 following HIF-1
siRNA was 2.1-fold (standard deviation [SD], 0.3-fold; n 
3). Altogether, therefore, reciprocal interactions between
HIF-1 and HIF-2 were apparent across a range of RCC
cells.
The interactive behavior of HIF- proteins was in apparent
contrast with that of HIF- mRNAs, which had not demon-
strated interactions in siRNA experiments (Fig. 2A, upper
parts). To pursue this, we analyzed changes in HIF-mRNA in
RCC4 cells, which exhibit large suppressive effects of HIF-2
overexpression on HIF-1 protein. No such effects were ob-
served on HIF-1 mRNA levels (Fig. 3A), confirming interac-
tion at the protein level. Since this interaction has not been
reported in non-RCC cells, we considered whether it might
represent effects on an alternative protein degradation path-
way(s) that becomes an important determinant(s) of HIF-
protein levels in VHL-defective cells. However, cycloheximide
chase experiments indicated that despite an approximately
threefold difference in steady-state HIF-1 protein levels in
RCC4 cells that did or did not overexpress HIF-2, the HIF-1
protein half-life was similar (Fig. 3B). Thus, it is most likely
that the interaction is mediated through effects on HIF- pro-
tein translation. To determine whether the effector mechanism
requires HIF-mediated transcription, a HIF-2 molecule con-
taining a five-amino-acid substitution in its DNA binding do-
main, that ablates HIF-2 transcriptional activity (19), was
created in pLZRS-IRES-GFP and used to infect RCC4 cells.
Results are shown in Fig. 3C and indicate that DNA binding is
necessary, suggesting, though not formally proving, that
HIF-2 transcriptional activity is required for suppression of
HIF-1.
Transcriptional selectivity for HIF-1 and HIF-2 among
genes expressed in RCC cells. Given these interactions be-
tween HIF- subunits, the unusual ratio of HIF-2 to HIF-1
expression in RCC cells and tumors, and the complete selec-
tivity for HIF-2 manifested by cyclin D1, we next sought to
analyze the transcriptional selectivity for HIF-1 or HIF-2 in
RCC cells among a wider group of genes. Five gene products
of potential relevance to different aspects of tumor biology,
BNip3 (a proapoptotic member of the Bcl-2 family), carbonic
anhydrase 9 (CAIX), glucose transporter 1 (GLUT-1), VEGF,
and TGF-, were studied.
BNip3, CAIX, and GLUT-1 were analyzed by immunoblot-
ting of whole-cell extracts. In the first set of experiments,
786-O cells were infected with retroviruses expressing HIF-1,
HIF-2, or GFP alone as described above. As before, expres-
sion of HIF-1 in 786-O cells suppressed HIF-2 (Fig. 4A,
upper two parts). Strikingly, for each of the HIF target gene
products, distinct HIF- isoform-specific responses were ob-
served. CAIX was strongly induced by infection with virus
expressing HIF-1, but not virus expressing HIF-2 (Fig. 4A,
FIG. 2. Interaction between HIF-1 and HIF-2 and effects on
cyclin D1 expression. (A) RNase protection assay of HIF-1, HIF-2,
and CCND1 mRNAs (U6 snRNA, loading control) in RCC4 cells after
treatment for 48 h with Oligofectamine alone (), HIF-1-directed
siRNA (H1), HIF-2-directed siRNA (H2), or control siRNA (C). (B
and D) Immunoblots, with the indicated antibodies, of whole-cell
lysates from RCC4 and SKRC28 cells that were infected with retroviral
supernatants made from pLZRS containing GFP alone (G), HIF-1
(H1), or HIF-2 (H2). (C and E) Immunoblots for HIF-1, HIF-2,
and -tubulin of RCC4 and SKRC28 whole-cell lysates after treatment
for 48 h with a control siRNA (C), HIF-1 siRNA (H1), or HIF-2
siRNA (H2). (F) Immunoblots for HIF-1, HIF-2, and -tubulin of
RCC4 whole-cell lysates treated with the previously indicated siRNAs
and then exposed to 1 mM MMOG for 18 h. Two independent exper-
iments for each condition are shown in panels B, C, D, E, and F.
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third part). GLUT-1 displayed the reverse pattern, with strik-
ing induction by HIF-2, and, like cyclin D1, was downregu-
lated following infection with virus expressing HIF-1, paral-
leling the downregulation of HIF-2 (Fig. 4A, fourth part).
Results for BNip3 were of particular interest. BNip3 was un-
responsive to HIF-1 but clearly downregulated by increased
expression of HIF-2 (Fig. 4A, bottom part).
Further experiments were performed with RCC4 and
SKRC28 cells (Fig. 4B to D). CAIX was again specifically
responsive to HIF-1, with downregulation in response to
HIF-1- but not HIF-2-directed RNA interference (RNAi).
Interestingly, downregulation was also observed in response to
HIF-2 overexpression, due to either direct suppression or
indirect effects via suppression of HIF-1 (Fig. 4B). The in-
ability of HIF-1 overexpression in RCC4 to further induce
CAIX levels may indicate that endogenous expression of this
gene product was already maximal in this cell type (Fig. 4B).
GLUT-1 again responded specifically to HIF-2, being down-
regulated by HIF-2 RNAi (Fig. 4C and D) and upregulated
by HIF-2 overexpression (Fig. 4B). These effects on GLUT-1
protein levels were also observed at the mRNA level (Fig. 4E).
Though the findings were not identical, BNip3 also responded
similarly to the pattern in 786-O cells. In keeping with down-
regulation by HIF-2, BNip3 levels were strikingly reduced in
RCC4 cells infected with retroviruses expressing HIF-2 and
increased by HIF-2-directed siRNA. However, in RCC4 and
SKRC28 cells BNip3 retained a positive response to HIF-1,
which has been described in non-RCC cell types but was not
observed in 786-O cells (Fig. 4B to D).
Effects on VEGF and TGF- expression were assayed by
enzyme-linked immunosorbent assay (ELISA) using tissue cul-
ture supernatant or cell extract, respectively. Following previ-
ous analyses of 786-O cells (39), effects of siRNA-mediated
HIF- suppression on VEGF secretion were examined in
RCC4 and SKRC28 cells, whereas effects on TGF- levels
were assessed in 786-O, RCC4, and SKRC28 cells. In each cell
FIG. 3. Analysis of suppression of HIF-1 by HIF-2 in RCC4
cells. (A) RNase protection assay of HIF-1 and HIF-2 mRNAs in
RCC4 cells infected with retroviral supernatants made from pLZRS
containing GFP alone (G), HIF-1 (H1), or HIF-2 (H2). (B) Rep-
resentative immunoblot for HIF-1 of RCC4 whole-cell lysates which
were infected with retroviral supernatants made from pLZRS contain-
ing GFP alone or HIF-2 and then treated with 100 M cycloheximide
(CHX) for 0, 1, 2, or 3 h. Note that to aid densitometric analysis of
signal decay, more extract was loaded from cells infected with retro-
viruses expressing HIF-2 than GFP alone so as to obtain sufficient
signal intensity at t  0. (C) Immunoblots for HIF-1, HIF-2, and
-tubulin of whole-cell lysates from RCC4 cells infected with retroviral
supernatants made from pLZRS containing GFP alone (G), HIF-2
(H2), or a HIF-2 DNA binding domain mutant (H2*). Two indepen-
dent experiments for each condition are shown in panels A and C.
FIG. 4. HIF- isoform transcriptional specificity in 786-O, RCC4,
and SKRC28 cells. (A and B) Immunoblots for HIF-1, HIF-2,
CAIX, GLUT-1, and BNip3 of 786-O and RCC4 whole-cell lysates
that were infected with retroviral supernatants made from pLZRS
containing GFP alone (G), HIF-1 (H1), or HIF-2 (H2). (C and D)
Immunoblots, with the indicated antibodies, of whole-cell lysates from
RCC4 and SKCR28 cells after treatment for 48 h with a control siRNA
(C), HIF-1 siRNA (H1), or HIF-2 siRNA (H2). (E) RNase protec-
tion assay of GLUT-1 mRNA in RCC4 cells infected with retroviral
supernatants made from pLZRS containing GFP alone (G), HIF-1
(H1), or HIF-2 (H2) and after treatment for 48 h with a control
siRNA (C), HIF-1 siRNA (H1), or HIF-2 siRNA (H2). Two inde-
pendent experiments for each condition are shown in panels A, B, C,
and D.
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line, VEGF and TGF- production was specifically reduced by
siRNA-mediated suppression of HIF-2 but not suppression
of HIF-1 (Fig. 5A and B).
HIF- isoform-specific patterns of gene expression differ
between RCC and non-RCC cell lines. The above findings
indicate that each of six HIF target genes displays a character-
istic HIF- isoform-specific response in a range of VHL-de-
fective RCC cells. These results predict that the unusual bias
toward HIF-2 expression in RCC cells would itself lead to
unusual patterns of HIF target gene expression. For instance,
negative regulation by HIF-2, and positive regulation by HIF-
1, of BNip3 predicts that in VHL-defective cells displaying a
strong bias to HIF-2 isoform expression, the response of
BNip3 to activation of the HIF pathway would be inverted. To
test this, we examined the effect of the HIF hydroxylase inhib-
itor MMOG on BNip3 expression in stable transfectants of
786-O and A498 cells re-expressing wild-type VHL. Both of
these cells express functional HIF-2 but not HIF-1. In keep-
ing with predictions, but in contrast with the results of studies
in other cell lines (3, 21), BNip3 was markedly downregulated
by MMOG in these cells (Fig. 5C). There were no effects on
the expression of BNip3 or HIF-2 in response to MMOG
treatment in the parental 786-O cell line (data not shown).
We next wanted to determine if the specific connections
between HIF- isoforms and particular target genes, and the
suppressive interactions between HIF- isoforms in VHL-de-
FIG. 5. Unusual patterns of HIF--dependent gene expression in RCC cells. (A) VEGF secretion by RCC4 and SKRC28 cells as determined
by ELISA of medium supernatant. Cells were treated with siRNAs directed against a control sequence (C), HIF-1 (H1), HIF-2 (H2), both
HIF-1 and HIF-2 (B), or Oligofectamine alone (). VEGF levels were normalized to cell number. Experiments were performed in triplicate
at least three times, and error bars correspond to 1 standard deviation. (B) Expression levels of TGF- in 786-O, RCC4, and SKRC28 cell lysates
as determined by ELISA. Cells were treated with siRNAs directed against a control sequence (C), HIF-1 (H1), HIF-2 (H2), both HIF-1 and
HIF-2 (B), or Oligofectamine alone (). TGF- expression levels in the cell lysates were normalized to total cellular protein content.
Experiments were performed in triplicate at least three times, and error bars correspond to 1 standard deviation. (C) Immunoblots for HIF-1,
HIF-2, and -tubulin of whole-cell lysates from 786-O/VHL and A498/VHL cells after exposure to normoxia (N) or 1 mM MMOG (M) for 18 h.
Two independent experiments for each condition are shown in panel C.
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fective RCC cell lines, differ from those in cells not derived
from VHL-associated cancer. To this end, studies were per-
formed with Caki-1 cells (an RCC cell line), HK-2 cells (a
human kidney proximal-tubule cell line), and MDA-MB 435
cells (a melanoma cell line, often considered to be breast
carcinoma), all of which are wild type for VHL.
Studies using siRNA revealed evidence for a pattern of
reciprocal suppression between HIF-1 and HIF-2 similar to
that defined in VHL-defective RCC cells; for instance, siRNA-
mediated suppression of HIF-2 was associated with upregu-
lation of HIF-1 in MMOG-treated cells, consistent with en-
hanced synthesis of the HIF-1 protein (Fig. 6C and D, right
parts). However, overexpression experiments demonstrated a
clear difference; for instance, overexpression of HIF-2 in
VHL-competent cells led to enhanced expression of HIF-1
(Fig. 6A and B). Similar results were obtained in stable trans-
fectants of RCC4 cells re-expressing wild-type VHL (Fig. 6E).
The positive interaction observed with overexpression in
RCC4/VHL but not RCC4 cells indicates that the change in
behavior is determined not by cell background but by the
presence of an intact VHL degradation pathway and is consis-
tent with previous data indicating that this pathway can be
readily saturated, leading to stabilization of HIF- subunits
following overexpression (31, 40). A likely explanation is there-
fore that in VHL wild-type cells there are two different types of
HIF- interaction taking place, competition in a saturable
VHL-mediated degradation pathway and the mutually sup-
pressive (negative) interaction defined above. Indeed, in
siRNA experiments, this negative interaction can be observed
between HIF-1 and HIF-2 in RCC4/VHL cells (data not
shown). Following VHL inactivation, the first process (compe-
tition for degradation) no longer operates so that the domi-
nating pattern of HIF- interaction apparently switches to one
of negative interaction.
Analysis of gene expression in Caki-1 and non-RCC cells
also revealed apparent differences in the transcriptional con-
nections of the HIF pathway. Some genes showed differences
in HIF- isoform specificity in cells derived from VHL-defec-
tive RCC versus other cell types, whereas other genes only
responded to the HIF pathway in cells derived from VHL-
defective RCC.
CAIX was specifically responsive to HIF-1 in all cell back-
grounds. Likewise, BNip3 appeared to behave similarly across
all cells, demonstrating positive regulation by HIF-1 and ei-
ther no clear regulation or negative regulation (Fig. 6A) by
HIF-2. Consistent with reports of cell type-restricted re-
sponses to hypoxia (2, 46), cyclin D1 was unresponsive to
RNAi-based suppression or retrovirus-mediated overexpres-
sion of either HIF- isoform in any cell other than those
derived from VHL-defective RCC. Of particular interest were
the responses of GLUT-1 and VEGF. In overexpression stud-
ies, GLUT-1 responded to both HIF-1 and HIF-2 (Caki-1)
or even dominantly to HIF-2 (MDA-MB 435), whereas stud-
ies of suppression by RNAi (Caki-1 and HK-2) indicated that
endogenous levels were largely maintained by HIF-1 with
minimal contribution from HIF-2 (Fig. 6A to D). Similar
results were observed when GLUT-1 was assayed in Caki-1
cells at the mRNA level (Fig. 6F, lanes 1 to 3). This pattern is
in marked contrast to that in the VHL-defective RCC cells,
where the contribution from HIF-1 was minimal, even in
RCC4 and SKRC28 cells, where this isoform was expressed at
substantial levels (compare Fig. 6C and D with Fig. 4C and D).
Interestingly, the switch to HIF-2 dependence of GLUT-1
was not reversed by VHL reconstitution in RCC4 (Fig. 6F).
This is consistent with observations in 786-O cells, where de-
pendence of GLUT-1 and certain other target genes on
HIF-2 rather than HIF-1 is not reversed by VHL reconsti-
tution (11, 39), suggesting that this is a cell background effect
observed in VHL-defective RCC but not directly attributable
to VHL itself. The response of VEGF also showed differences
between the VHL wild-type and VHL-defective cells (compare
Fig. 6G and 5A). For instance, in distinction from results in
VHL-defective cells, VEGF production was clearly downregu-
lated by HIF-1-directed RNAi in Caki-1 cells.
Gene expression patterns in VHL-associated renal lesions.
To pursue the clinical relevance of the HIF- isoform tran-
scriptional selectivity manifest in cultured RCC cells, we next
examined immunohistochemical staining patterns in nephrec-
tomy specimens obtained from VHL patients. In such kidneys
we have previously demonstrated that activation of the HIF
system is an early feature of disease, with HIF-1 being man-
ifest in very early lesions detectable even as single tubular cells,
whereas HIF-2 upregulation appeared to occur later with
progressively stronger staining in larger and more dysplastic
lesions, and overt carcinoma (26). This is illustrated in Fig. 7,
where it can be seen that HIF-1 staining is strong in the small,
presumably early, lesion (row A) and maintained in the larger
cystic (row B) and overtly cancerous lesions (row C), whereas
HIF-2 is much more strongly expressed in the cystic and
cancerous lesions. In association with this, staining of serial
sections for CAIX, BNip3, and cyclin D1 shows that while
CAIX is expressed (like HIF-1) in all lesions, BNip3 and
cyclin D1 show strikingly different patterns, with BNip3 stron-
gest in early lesions that express little or no HIF-2 and cyclin
D1 being essentially confined to later lesions that do express
HIF-2.
Effects of HIF-1 and HIF-2 overexpression on growth of
RCC tumor xenografts. Finally, we tested the effects of en-
hancing expression of HIF-1 or HIF-2 on the growth of
RCC cells as tumor xenografts. In a first set of experiments,
786-O cells were infected with retroviruses expressing HIF-1,
HIF-2, or GFP alone with the same protocol that was used
for the gene expression experiments. Unselected pools of in-
fected cells were implanted subcutaneously into nude mice.
Whereas four of five injections of 786-O cells bearing control
retrovirus (expressing GFP alone) formed tumors, none of the
injections of 786-O infected with retrovirus expressing HIF-1
formed tumors. In contrast, 786-O cells infected with retrovi-
rus expressing HIF-2 formed tumors that grew at an en-
hanced rate compared to the cells infected with control virus,
suggesting disparate effects of HIF-1 and HIF-2 on tumor
growth. To pursue this, we made a further set of retroviruses
expressing HIF-1 or HIF-2 as part of a bicistronic mRNA
also expressing a neomycin resistance gene in pBMN-Z-IRES-
Neo. These viruses were used to infect 786-O cells and select
pools of cells overexpressing HIF-1, HIF-2, or empty vector.
Aliquots of these cells were then analyzed for growth as mono-
layers under standard tissue culture conditions or for growth as
tumors after subcutaneous injection into nude mice. In these
experiments, injected cells were mixed with Matrigel with the
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FIG. 6. HIF- isoform transcriptional selectivity in MDA-MB 435, Caki-1, and HK-2 cells. (A and B) Immunoblots, with the indicated antibodies,
of MDA-MB 435 and Caki-1 whole-cell lysates that were infected with retroviral supernatants made from pLZRS containing GFP alone (G), HIF-1
(H1), or HIF-2 (H2) and then exposed to normoxia or 1 mM MMOG for the final 18 h. (C and D) Immunoblots, with the indicated antibodies, of
whole-cell lysates from HK-2 and Caki-1 cells after treatment for 48 h with control siRNA (C), HIF-1 siRNA (H1), or HIF-2 siRNA (H2) and then
exposed to normoxia or 1 mM MMOG for the final 18 h. (E) Immunoblots for HIF-1 and HIF-2 of RCC4/VHL whole-cell lysates that were infected
with retroviral supernatants made from pLZRS containing GFP alone (G), HIF-1 (H1), or HIF-2 (H2). Two independent experiments for each
condition are shown in panels A, B, C, D, and E. (F) RNase protection assay of GLUT-1 mRNA in Caki-1, RCC4/VHL (Normoxia), and RCC4/VHL
(Hypoxia) cells after treatment for 48 h with a control siRNA (C), HIF-1 siRNA (H1), or HIF-2 siRNA (H2). (G) Secreted levels of VEGF in Caki-1
as determined by ELISA of medium supernatant. Cells were treated with siRNAs directed against a control sequence (C), HIF-1 (H1), HIF-2 (H2),
both HIF-1 and HIF-2 (B), or Oligofectamine alone () and then exposed to normoxia or 1 mM MMOG for the final 18 h. VEGF levels were
normalized to cell number. Experiments were performed in triplicate at least three times, and error bars correspond to 1 standard deviation.
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aim of enhancing the tumor take so as to permit better com-
parison of growth rates. Immunoblotting revealed that moder-
ate overexpression of HIF-1 and HIF-2 was achieved in
these cells (Fig. 8A). However, when they were grown as
monolayers under standard tissue culture conditions, no dif-
ferences in the growth rate or maximum cell number were
observed (Fig. 8B). In contrast, marked differences were again
observed in tumor growth. Two sets of experiments, using
separately derived pools of cells were performed. Whereas
infection with retrovirus expressing HIF-2 clearly enhanced
tumor growth in these experiments, infection with retrovirus
expressing HIF-1 had the reverse effect (Fig. 8C and D).
Though some variability was seen in growth curves of individ-
ual tumors expressing HIF-1 (Fig. 8D), the largest experi-
ment showed significant retardation of growth for this group of
tumors (Fig. 8C).
DISCUSSION
This study demonstrates that, despite close similarities be-
tween the HIF- isoforms, differential activation of HIF-1 or
HIF-2 pathways in VHL-defective RCC cells has nonequiva-
lent or even opposing effects on gene expression and experi-
mental tumor growth. Our investigations differ somewhat from
previous studies of the role of HIF in RCC tumor growth, in
which two different groups used either mutated HIF-1 (27) or
mutated HIF-2 molecules (18, 19), which escape VHL rec-
ognition, to test for opposition of the tumor-suppressive effect
of reintroducing wild-type VHL into 786-O cells. We used
wild-type HIF- isoforms in assays for effects on tumor growth
and directly compared the effects of augmenting HIF-1 or
HIF-2 on the growth of 786-O cells as subcutaneous tumors
in nude mice. Our data indicate that the apparent discrepancy
between the two previous studies arises from real differences
between the actions of HIF-1 and HIF-2, with HIF-2 hav-
ing positive effects on tumor growth and HIF-1 having neg-
ative effects on tumor growth in this setting. Since we also
demonstrate suppressive interaction between HIF- isoforms,
we cannot as yet distinguish whether suppression of tumor
growth by HIF-1 arises from direct effects, indirect effects due
to downregulation of HIF-2, or a combination of both possi-
bilities. Interestingly, in contrast to effects on tumor growth, no
effects were observed on monolayer growth under standard
tissue culture conditions, as has been observed in assays of
VHL tumor suppressor function based on re-introduction of
wild-type VHL into VHL-defective RCC cells (12, 19, 49).
Consistent with differential effects on tumor growth were
differential effects on the expression of specific genes with
putative pro- and antitumorigenic effects. In particular,
HIF-1 positively regulated BNip3 but had no effect on cyclin
D1, TGF-, and VEGF, whereas HIF-2 negatively regulated
BNip3 and positively regulated cyclin D1, TGF-, and VEGF.
BNip3 is a member of the Bcl-2 family of apoptosis-regulating
proteins and activates caspase-independent necrosis-like cell
death by opening the mitochondrial permeability transition
pore (43). In most cells, the protein is strongly induced by
hypoxia, and an involvement in hypoxic tumor necrosis has
been postulated (3, 21). Cyclin D1 is one of the main G1-phase
cyclins. Its expression is associated with G1-to-S transition in
the cell cycle and upregulated in many types of cancer by a
variety of mechanisms (38). TGF-, on the other hand, is a
potent renal cell mitogen that activates the epidermal growth
factor receptor pathway and has been proposed to initiate an
autocrine loop with this receptor when VHL is inactivated in
FIG. 7. Immunohistochemical analysis for HIF- and transcriptional targets in sections from the kidney of a patient with VHL disease.
Immunohistochemical analysis, with the indicated antibodies, of serial sections of representative lesions. Panels: A, an early multicellular lesion;
B, a renal cyst; C, an overt clear-cell RCC. Final magnifications: A, 	360; B and C, 	240.
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renal cells (6). CAIX and GLUT-1 are both upregulated in
many forms of cancer, but their contribution to tumor growth
is less clear. GLUT-1 was found to be a specific HIF-2 target
in VHL-defective RCC but not in other cells, whereas CAIX
was found to be a specific HIF-1 target in both RCC and
non-RCC cells, as has been reported for genes encoding a
range of glycolytic enzymes (11). Interestingly, though upregu-
lation of CAIX is commonly observed in RCC (25), reduced
staining has been correlated with poorer prognosis in RCC in
a recent clinical series (4).
Based on known functions, it seems likely that the HIF-
isoform transcriptional selectivity manifest by one or more of
FIG. 8. Effect of overexpression of HIF-1 or HIF-2 on growth of 786-O cells as monolayers or tumor xenografts. (A) Immunoblots for
HIF-1 and HIF-2 of whole-cell lysates from 786-O polyclonal pools of cells that were selected with G418 after infection with retroviral
supernatants made from pBMN-Neo containing an empty cassette (LacZ spliced out) as a control (C), HIF-1 (H1), or HIF-2 (H2). (B) Growth
of selected polyclonal pools of 786-O cells stably infected with the indicated retroviruses. Growth was measured under standard tissue culture
conditions for 9 days, and there was no significant difference in the proliferation rate between the groups. Error bars indicate standard deviations.
(C) Tumor weights approximately 5.5 weeks after subcutaneous injection of polyclonal pools of 786-O cells stably infected with the indicated
retroviruses. There were 14 tumors analyzed for each group, and error bars indicate 1 standard error. Two-tailed, unpaired Student t tests
comparing each HIF- overexpressing group to the control group were performed, and statistically significant difference is indicated by asterisks
for P 
 0.005. (D) Growth curves indicated as tumor volume over a 90-day period after subcutaneous injection of polyclonal pools of 786-O cells
stably infected with the indicated retroviruses. Five mice with single tumors were analyzed for each group.
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the genes analyzed could contribute to differential effects of
the HIF- isoforms on VHL-associated RCC growth. How-
ever, the exact contribution of individual genes was not de-
fined. Given the complexity of the HIF transcriptional cascade
and the large number of direct and indirect HIF targets iden-
tified in gene expression arrays (11, 15, 47), such an analysis
remains a considerable task. Nor can it be deduced that other
potentially protumorigenic and antitumorigenic HIF target
genes will fall into the above pattern, particularly as in non-
RCC settings the balance of evidence favors a positive action
of HIF-1 on tumor growth (37). Presumably, the set of
HIF-1 and HIF-2 targets in part reflects differences in the
physiological role of these proteins in the response to hypoxia
that are as yet unclear. Interestingly, HIF-1 has recently been
demonstrated to antagonize Myc and induce cell cycle arrest by
complexing Myc in a transcriptionally inactive form (20). In
future studies it will be interesting to determine if this property
is shared by HIF-2 and whether it contributes to effects on
RCC tumor growth.
Though HIF- transcriptional selectivity was observed in all
cells, there were important differences between what were es-
sentially two distinct patterns, that observed in VHL-defective
RCC cells and that observed in all other cells, including the
VHL-competent RCC line Caki-1. Differences in transcrip-
tional targeting were of two types. First, some genes such as
cyclin D1 appeared to be transcriptional targets of HIF-2 only
in VHL-defective cells. TGF- may also fall into this category
but has been less extensively studied in VHL-competent cells.
Second, some genes, such as those for GLUT-1 and VEGF,
appeared to be specific HIF-2 targets in VHL-defective RCC
cells whereas in VHL-competent Caki-1 and non-RCC cells
they appear potentially responsive to both HIF- isoforms. For
instance, for GLUT-1, HIF- suppression by siRNA in Caki-1
and non-RCC cells indicates clear dependence on HIF-1,
whereas overexpression studies show that enhanced expression
of both isoforms, but particularly HIF-2, can clearly drive
GLUT-1 expression. These findings correlate well with pub-
lished work with other non-RCC cells that has shown that
GLUT-1 is induced by overexpression of both HIF- isoforms
in VHL wild-type HEK 293 cells (11) but predominantly de-
pendent on endogenous HIF-1, as revealed by genetic inac-
tivation studies (39). In contrast, in VHL-defective RCC cells,
neither HIF-1 siRNA nor HIF-1 overexpression had any
effect on GLUT-1, even in cells retaining substantial levels of
HIF-1 that was transcriptionally active on other target genes.
Though the mechanistic basis of this difference is unclear, the
simplest explanation is that a specific transcriptional connec-
tion between HIF-1 and these genes is missing in VHL-
defective RCC.
It is difficult to distinguish whether these unusual properties
of the HIF system are newly acquired during RCC develop-
ment as further events following VHL inactivation or whether
they reflect unusual intrinsic properties of the cells giving rise
to VHL-associated RCC. The clear differences from the re-
lated renal cell line Caki-1 favor the occurrence of additional
events, though concordance across a number of RCC lines
suggests that such events must occur at high probability fol-
lowing VHL inactivation.
Also of interest in understanding the unusual properties of
the HIF system in VHL-defective RCC cells is the demonstra-
tion of suppressive interactions between HIF- isoforms.
Though a natural antisense to the 3 untranslated region of
HIF-1 has been described (aHIF) (41) that may suppress
HIF-1 mRNA in RCC cells, the suppressive interaction we
observed was not manifest on the mRNA level, indicating that
it represents a different process. Our results are consistent with
an action on HIF- protein translation, though we have not yet
defined the mechanism. Whether such a process extends to
other components of hypoxia pathways such as the translation
of HIF target genes is unclear, though in general we found that
changes in expression of HIF target gene transcripts and pro-
tein products were concordant. Whatever the mechanism, our
analysis suggests that the interaction we describe is not a dis-
tinct property of the HIF system in VHL-defective cells;
rather, it is uncovered as a direct consequence of VHL inac-
tivation blocking the HIF degradation pathway, which is satu-
rable, leading to competitive interactions between HIF-1 and
HIF-2 in the opposite direction of that seen in VHL-compe-
tent cells. Nevertheless, this phenomenon could well contrib-
ute to the unusual dominant expression of HIF-2 over
HIF-1 expression observed in VHL-defective RCC, since up-
regulation of HIF-2 would now be anticipated to downregu-
late HIF-1 and vice versa. Such a scenario begs the following
question: is upregulation of HIF-2 or downregulation of
HIF-1 the primary event in driving the observed bias? Cur-
rently, we cannot answer this question, though it is of interest
that a recent report has described a shortened HIF-1 tran-
script in 786-O cells (44) and in previous work we have ob-
served a shortened HIF-1 protein species in A498 cells (M. E.
Cockman, Ph.D. thesis, Oxon, 2003), suggesting that at least in
some cases inactivation of HIF-1 may be a discrete event.
Overall, our data indicate that HIF-1 and HIF-2 have
functionally distinct roles in the biology of VHL-defective
RCC, with HIF-2 promoting and HIF-1 retarding tumor
growth, and that the HIF system behaves unusually in this
setting in a number of ways. There is growing interest in the
development of HIF inhibitors as anticancer agents (24, 33,
37). Our findings clearly have relevance to targeting the HIF
system in cancer therapy and emphasize the importance of
considering isoform-specific effects.
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